Monotherapy: 200 mg bid. Dose modifications for adverse reactions: 1st dose reduction: 150 mg bid; 2nd dose reduction: 100 mg bid; 3rd dose reduction: 50 mg bid. Combination therapy w/ fulvestrant, tamoxifen or aromatase inhibitor: 150 mg bid. Dose modifications for adverse reactions: 1st dose reduction: 100 mg bid; 2nd dose reduction: 50 mg bid. Early breast cancer
Take continuously for 2 yr, or until disease recurrence or unacceptable toxicity. Concomitant use w/ strong CYP3A inhibitors other than ketoconazole in patient w/ recommended starting dose of 200 mg or 150 mg bid
Reduce dose to 100 mg bid, patient who had dose reduction to 100 mg bid
May further reduce dose to 50 mg bid. Severe hepatic impairment (Child Pugh-C)
Reduce frequency to once daily.